The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies
Abstract
PURPOSE: To investigate the effect of recombinant human erythropoietin (epoetin beta) on anemia, transfusion need, and quality of life (QOL) in severely anemic patients with low-grade non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), or multiple myeloma (MM). PATIENTS AND METHODS: Transfusion-dependent patients with NHL (n = 106), CLL (n = 126), or MM (n = 117) and a low serum erythropoietin concentration were randomized to receive epoetin beta 150 IU/kg or placebo subcutaneously three times a week for 16 weeks. Primary efficacy criteria were transfusion-free and transfusion- and severe anemia–free survival (hemoglobin [Hb] > 8.5 g/dL) between weeks 5 to 16. Response was defined as an increase in Hb ≥ 2 g/dL with elimination of transfusion need. QOL was assessed by the Functional Assessment of Cancer Therapy scale. RESULTS: Transfusion-free (P = .0012) survival and transfusion- and severe anemia–free survival (P = .0001) were significantly greater in the epoetin beta group versus placebo (Wald χ 2 test), giving a relative risk reduction of 43% and 51%, respectively. The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P < .0001). After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P < .05); this improvement correlated with an increase in Hb concentration (≥ 2 g/dL). A target Hb that could be generally recommended could not be identified. CONCLUSION: Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Multiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Harris, N. L. (1995) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(00)80051-4 · Cited by 527
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
Ludwig, H., Fritz, E., Kotzmann, H., Höcker, P., Gisslinger, H., & Barnas, U. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222402 · Cited by 443
Cited by
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
Knight, K., Wade, S., & Balducci, L. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.008 · Cited by 878
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M., Weingart, O., Kluge, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60502-x · Cited by 597
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Metadata
- Authors
- Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., & Messinger, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-15
- Volume
- 20
- Issue
- 10
- Pages
- 2486-2494
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002395765
- Cited by
- 310
- References
- 18
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. https://app.cochat.ai/papers/10.1200/jco.2002.08.131
- The paper
- Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., & Messinger, D. (2002). Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.08.131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.